New patient trials surrounding this compound, specifically the 120 milligram formulation ZPHC ZPHC, suggest a impressive impact on weight reduction and linked metabolic factors. Researchers posit that this innovative agonist , influencing both GLP-1 and GIP systems, could offer a noteworthy improvement in the approach of obesity and related metabo